Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Net Cash Flow (2017 - 2024)

Solid Biosciences' Net Cash Flow history spans 8 years, with the latest figure at $15.9 million for Q4 2024.

  • For Q4 2024, Net Cash Flow fell 36.5% year-over-year to $15.9 million; the TTM value through Dec 2024 reached $6.3 million, up 107.55%, while the annual FY2024 figure was $6.3 million, 107.79% up from the prior year.
  • Net Cash Flow for Q4 2024 was $15.9 million at Solid Biosciences, up from -$31.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $113.8 million in Q1 2021 and bottomed at -$90.9 million in Q3 2021.
  • The 5-year median for Net Cash Flow is -$9.1 million (2020), against an average of -$6.3 million.
  • The largest annual shift saw Net Cash Flow skyrocketed 1035.32% in 2022 before it crashed 670.37% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $1.2 million in 2020, then skyrocketed by 651.24% to $9.4 million in 2021, then surged by 1035.32% to $106.4 million in 2022, then tumbled by 76.51% to $25.0 million in 2023, then tumbled by 36.5% to $15.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Net Cash Flow are $15.9 million (Q4 2024), -$31.4 million (Q3 2024), and -$21.6 million (Q2 2024).